CoChat

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Open access
Ribas, Antoni, Medina, Theresa, Kirkwood, John M., Zakharia, Yousef, Gonzalez, Rene, Davar, Diwakar, Chmielowski, Bartosz, Campbell, Katie M., Bao, Riyue, Kelley, Heather, Morris, Aaron, Mauro, David, Wooldridge, James E., Luke, Jason J., Weiner, George J., Krieg, Arthur M., Milhem, Mohammed M. · 2021 · Cancer Discovery

Published version of a preprint

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Patients with advanced melanoma that is resistant to PD-1 blockade therapy have limited treatment options. Vidutolimod (formerly CMP-001), a virus-like particle containing a CpG-A Toll-like receptor 9 (TLR9) agonist, may reverse PD-1 blockade resistance by triggering a strong IFN response to induce and attract antitumor T cells. In the dose-escalation part of this phase Ib study, vidutolimod was administered intratumorally at escalating doses with intravenous pembrolizumab to 44 patients with advanced melanoma who had progressive disease or stable disease on prior anti–PD-1 therapy. The combination of vidutolimod and pembrolizumab had a manageable safety profile, and durable responses were observed in 25% of patients, with tumor regression in both injected and noninjected lesions, including visceral lesions. Patients who responded to vidutolimod and pembrolizumab had noninflamed tumors at baseline and induction of an IFNγ gene signature following treatment, as well as increased systemic expression of the IFN-inducible chemokine CXCL10. Significance: In this phase Ib study in patients with advanced melanoma, intratumoral TLR9 agonist vidutolimod in combination with pembrolizumab had a manageable safety profile and showed promising clinical activity, supporting the further clinical development of vidutolimod to overcome PD-1 blockade resistance through induction of an IFN response. See related commentary by Sullivan, p. 2960. This article is highlighted in the In This Issue feature, p. 2945

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-0425

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Antitumor activity of vidutolimod plus pembrolizumab. A, Best percent change in SLD of target lesions from baseline. B, Percent change from baseline in SLD of target lesions over time. The bars (A) and lines (B) are colored on the basis of best overall response by RECIST v1.1 as determined by the investigator. C, Duration of vidutolimod treatment, onset, and DOR for each patient with a RECIST v1.1 response (n = 11) and patients with an iRECIST response (n = 2). RECIST v1.1 disease status shown was based on investigator assessment. Representative photographs (D) and radiologic imaging (E and F) demonstrating tumor regression of two injected scalp metastases (D), noninjected visceral lung metastases (E), and noninjected liver (F, top) and groin (F, bottom) metastases from three different patients. aFive patients with missing or incomplete postbaseline disease assessments were not included. bPatients had initial PD per RECIST v1.1 and were later shown to have a PR per iRECIST as determined by blinded central review (n = 2). cPatients with CR had less than 100% target lesion regression (target lymph nodes were less than 1.0 cm in diameter and met the RECIST v1.1 definition of CR). EOT, end of treatment; SLD, sum of longest diameters.
Figure 1. Antitumor activity of vidutolimod plus pembrolizumab. A, Best percent change in SLD of target lesions from baseline. B, Percent change from baseline in SLD of target lesions over time. The bars (A) and lines (B) are colored on the basis of best overall response by RECIST v1.1 as determined by the investigator. C, Duration of vidutolimod treatment, onset, and DOR for each patient with a RECIST v1.1 response (n = 11) and patients with an iRECIST response (n = 2). RECIST v1.1 disease status shown was based on investigator assessment. Representative photographs (D) and radiologic imaging (E and F) demonstrating tumor regression of two injected scalp metastases (D), noninjected visceral lung metastases (E), and noninjected liver (F, top) and groin (F, bottom) metastases from three different patients. aFive patients with missing or incomplete postbaseline disease assessments were not included. bPatients had initial PD per RECIST v1.1 and were later shown to have a PR per iRECIST as determined by blinded central review (n = 2). cPatients with CR had less than 100% target lesion regression (target lymph nodes were less than 1.0 cm in diameter and met the RECIST v1.1 definition of CR). EOT, end of treatment; SLD, sum of longest diameters.CC BY-NC-ND · PubMed Central
Figure 2. Chemokine induction and transcriptomic analyses. A, Box and whisker plot of serum CXCL10 concentrations preinjection and 2, 4, and 24 hours postinjection after the first vidutolimod injection and the third vidutolimod injection (schedule A, week 3; schedule B, week 5). Mean values are indicated by “x” symbols and outliers are shown as circles. The fold change in CXCL10 (B) and IL6 (C) at 24 hours from baseline across response groups. Both RECIST v1.1 responders (n = 11) and iRECIST responders (n = 2) are included in the CR/PR/iPR group. Horizontal lines indicate median values. D, Heat map of gene expression across genes associated with the IFNγ pathway and immune cell infiltration for 25 baseline samples taken from 22 patients. Three patients had two available biopsy samples each (archival and baseline) and both were analyzed (indicated by brackets underneath the heat map). Samples (x-axis) were sorted by decreasing frequency of CD8+ T cells in the full tissue (measured by IHC; bar chart) and by RECIST v1.1 best overall response (colored bars across the top of the figure). PD-L1–positive full tissue H-score is also shown (measured by IHC). E, Heat map of gene expression across paired baseline and on-study tumor biopsies as indicated by pretreatment and posttreatment bars (gray/white) across the top of the figure for 12 biopsies taken from five patients. The responding patient on the left had two posttreatment biopsies; the left biopsy was taken from an injected lesion, and the right biopsy was taken from a noninjected lesion. All other posttreatment biopsies were taken from injected lesions. Gray shading is used to indicate the patient identity between D and E. aBelow quantitation limit values were set to the lower limit of quantitation and above quantitation limit values were set to the upper limit of quantitation. bValues capped at 50 for plotting purposes. cInadequate samples for this metric. FPKM, fragments per kilobase of transcript per million mapped reads; H-score, histology score; iPR, PR by iRECIST; SD, standard deviation.
Figure 2. Chemokine induction and transcriptomic analyses. A, Box and whisker plot of serum CXCL10 concentrations preinjection and 2, 4, and 24 hours postinjection after the first vidutolimod injection and the third vidutolimod injection (schedule A, week 3; schedule B, week 5). Mean values are indicated by “x” symbols and outliers are shown as circles. The fold change in CXCL10 (B) and IL6 (C) at 24 hours from baseline across response groups. Both RECIST v1.1 responders (n = 11) and iRECIST responders (n = 2) are included in the CR/PR/iPR group. Horizontal lines indicate median values. D, Heat map of gene expression across genes associated with the IFNγ pathway and immune cell infiltration for 25 baseline samples taken from 22 patients. Three patients had two available biopsy samples each (archival and baseline) and both were analyzed (indicated by brackets underneath the heat map). Samples (x-axis) were sorted by decreasing frequency of CD8+ T cells in the full tissue (measured by IHC; bar chart) and by RECIST v1.1 best overall response (colored bars across the top of the figure). PD-L1–positive full tissue H-score is also shown (measured by IHC). E, Heat map of gene expression across paired baseline and on-study tumor biopsies as indicated by pretreatment and posttreatment bars (gray/white) across the top of the figure for 12 biopsies taken from five patients. The responding patient on the left had two posttreatment biopsies; the left biopsy was taken from an injected lesion, and the right biopsy was taken from a noninjected lesion. All other posttreatment biopsies were taken from injected lesions. Gray shading is used to indicate the patient identity between D and E. aBelow quantitation limit values were set to the lower limit of quantitation and above quantitation limit values were set to the upper limit of quantitation. bValues capped at 50 for plotting purposes. cInadequate samples for this metric. FPKM, fragments per kilobase of transcript per million mapped reads; H-score, histology score; iPR, PR by iRECIST; SD, standard deviation.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 180

Metadata

Authors
Ribas, A., Medina, T., Kirkwood, J. M., Zakharia, Y., Gonzalez, R., Davar, D., Chmielowski, B., Campbell, K. M., Bao, R., Kelley, H., Morris, A., Mauro, D., Wooldridge, J. E., Luke, J. J., Weiner, G. J., Krieg, A. M., & Milhem, M. M.
Affiliations
  • University of California, Los Angeles (US)
  • University of Colorado Cancer Center (US)
  • UPMC Hillman Cancer Center (US)
  • University of Iowa (US)
  • 5Checkmate Pharmaceuticals, Inc., Cambridge, Massachusetts.
Corresponding author
Ribas, Antoni
Venue
Cancer Discovery
Published
2021-07-29
Volume
11
Issue
12
Pages
2998-3007
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3186872020
Cited by
180
References
27
Citations by year
2026: 36 · 2025: 42 · 2024: 31 · 2023: 31 · 2022: 36 · 2021: 4
FWCI
9.28
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
Funders
  • Parker Institute for Cancer Immunotherapy (NA)
  • National Cancer Institute (R35CA197633, T32CA009120)
  • Cancer Research Institute Irvington (Postdoctoral Fellowship Program)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
CpG-A, Toll-like receptor 9 agonist, anti-PD-1 resistance, metastatic melanoma, pembrolizumab, intratumoral immunotherapy, interferon-gamma response, CXCL10, virus-like particles, combination immunotherapy, dose escalation
MeSH terms
Adjuvants, Immunologic, Humans, Melanoma, T-Lymphocytes, Toll-Like Receptor 9, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.